Leveraging Platform Processes For Developing And Accelerating Novel Gene And Cancer Therapeutics

This year, the FDA released its long-anticipated draft guidance for the Platform Technology Designation Program, a pivotal step forward for drug development. This guidance allows drug developers to utilize Platform Technology data from approved drugs when similar platforms are employed, expediting the approval process and improving patient access to therapies.

In the webinar below, Catalent’s George Buchman discusses the company’s approach to platform processes and its strategies for securing an integrated supply chain, emphasizing the importance of critical starting materials. Nathalie Clement from Siren also shares insights on the company’s groundbreaking work in combining AAV gene therapy with cytokine immunotherapy to create a powerful new treatment modality for cancer, highlighting how collaborating with Catalent has accelerated the development of these innovative therapies.

Watch the full presentation to discover the advantages of platform processes for advancing novel gene therapies, the role of robust partnerships in ensuring patient access to curative treatments, and how these collaborative efforts are shaping the future of therapeutic development.